ATE207760T1 - Hiv immunogene komplexe - Google Patents

Hiv immunogene komplexe

Info

Publication number
ATE207760T1
ATE207760T1 AT94917313T AT94917313T ATE207760T1 AT E207760 T1 ATE207760 T1 AT E207760T1 AT 94917313 T AT94917313 T AT 94917313T AT 94917313 T AT94917313 T AT 94917313T AT E207760 T1 ATE207760 T1 AT E207760T1
Authority
AT
Austria
Prior art keywords
immunogenic complexes
hiv immunogenic
hiv
complexes
concanvalin
Prior art date
Application number
AT94917313T
Other languages
English (en)
Inventor
Anthony Louis Devico
Ranajit Pal
Mangalasseril G Sarngadharan
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE207760T1 publication Critical patent/ATE207760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94917313T 1993-05-07 1994-05-06 Hiv immunogene komplexe ATE207760T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6092693A 1993-05-07 1993-05-07
PCT/US1994/005020 WO1994026305A1 (en) 1993-05-07 1994-05-06 Hiv immunogenic complexes

Publications (1)

Publication Number Publication Date
ATE207760T1 true ATE207760T1 (de) 2001-11-15

Family

ID=22032603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917313T ATE207760T1 (de) 1993-05-07 1994-05-06 Hiv immunogene komplexe

Country Status (10)

Country Link
US (6) US5843454A (de)
EP (1) EP0699077B1 (de)
JP (1) JPH08510246A (de)
AT (1) ATE207760T1 (de)
AU (1) AU680916B2 (de)
DE (1) DE69428896T2 (de)
DK (1) DK0699077T3 (de)
ES (1) ES2166779T3 (de)
PT (1) PT699077E (de)
WO (1) WO1994026305A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165710A (en) * 1989-10-23 2000-12-26 Robinson; James E. Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO1998000535A2 (en) * 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
FR2789590B1 (fr) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird Compositions immunogenes utilisables comme vaccins
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
AU7862500A (en) * 1999-10-08 2001-04-23 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
FR2799974B1 (fr) * 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
US6503736B1 (en) * 1999-11-12 2003-01-07 BIOMéRIEUX, INC. Antibodies to crosslinkers and methods for using the same
AU9466701A (en) 2000-09-22 2002-04-02 Univ Duke Immunogen
US7033593B2 (en) * 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2431212A1 (en) * 2000-12-27 2002-07-25 Richard T. Wyatt Immunogenic proteoliposomes, and uses thereof
AU2002335932B2 (en) * 2001-03-21 2007-11-01 Altarex Medical Corp. Therapeutic compositions that alter the immune response
DE60237704D1 (de) * 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US20050260208A1 (en) * 2002-04-11 2005-11-24 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
EP1554392A4 (de) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7811580B2 (en) * 2002-05-07 2010-10-12 Novartis Vaccines & Diagnostics, Inc. Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent
CA2490804C (en) 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US20060014148A1 (en) * 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
JP4038679B2 (ja) * 2003-05-13 2008-01-30 住友電気工業株式会社 半導体レーザーバーの固定用治具
WO2005111621A2 (en) * 2004-04-16 2005-11-24 Uab Research Foundation Molecular scaffolds for hiv-1 epitopes
US8206720B2 (en) 2004-06-08 2012-06-26 Novartis Vaccines & Diagnostics, Inc Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes
WO2006026097A2 (en) * 2004-08-25 2006-03-09 Vijay Ramakrishnan Pegylation of antibodies against hiv
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
CA2585574A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
WO2006084179A2 (en) 2005-02-03 2006-08-10 Novartis Vaccines And Diagnostics Inc. Hiv tat-cd4 hybried molecules and methods of use thereof
WO2006091455A2 (en) * 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20100104580A1 (en) * 2008-09-03 2010-04-29 Philadelphia Health & Education Corporation D/B/A Altered Immunogenic Landscape in HIV-1 Envelope Proteins
WO2010051215A1 (en) * 2008-10-31 2010-05-06 Proteonova, Inc. Methods for making hiv vaccines and related compositions
US8340810B2 (en) * 2008-10-31 2012-12-25 Spectra Logic Corp. Robotic storage library with queued move instructions and method of queuing such instructions
US9228171B2 (en) 2010-02-05 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulatory B cells (tBREGS) and their use
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012255266B2 (en) 2011-05-17 2017-05-25 California Institute Of Technology Human immunodeficiency virus neutralizing antibodies and methods of use thereof
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20150175678A1 (en) * 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015077789A2 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
US20160362478A1 (en) * 2014-02-10 2016-12-15 Navid Madani Cd4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69010523D1 (de) * 1989-03-03 1994-08-18 Microgenesys Inc Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
AU653366B2 (en) * 1990-09-28 1994-09-29 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus

Also Published As

Publication number Publication date
US5518723A (en) 1996-05-21
DE69428896D1 (de) 2001-12-06
US20030039663A1 (en) 2003-02-27
AU680916B2 (en) 1997-08-14
EP0699077A1 (de) 1996-03-06
US6465172B1 (en) 2002-10-15
US5843454A (en) 1998-12-01
US6328973B1 (en) 2001-12-11
DK0699077T3 (da) 2002-01-21
PT699077E (pt) 2002-04-29
ES2166779T3 (es) 2002-05-01
AU6907394A (en) 1994-12-12
DE69428896T2 (de) 2002-06-20
US6030772A (en) 2000-02-29
WO1994026305A1 (en) 1994-11-24
EP0699077B1 (de) 2001-10-31
JPH08510246A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
ATE207760T1 (de) Hiv immunogene komplexe
OA09499A (en) Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) gp 120 and methods of use.
CA2082948A1 (en) Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
EP0724651A4 (de) Synthetische humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch
GR3035501T3 (en) Peptide-carbohydrate conjugates generating t-cell immunity.
GEP20032902B (en) Mixture of Recombinant Vaccinia Vectors as Polyenv Vaccines for HIV
EP0911036A3 (de) Dualer Träger für immunogene Konstrukte
ES2011334A6 (es) Metodo para la deteccion de anticuerpos de hiv-2.
DE68906366D1 (en) Cd4-polypeptidderivate.
MY119031A (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
AU4985496A (en) Administration of a cyclosporine-specific monoclonal antibody that cross-reacts with hiv-1 p24 gag to treat hiv infection
IT1187753B (it) Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3772087D1 (de) Schnellkupplung fuer rohre, pfaehle und aehnliches.
DE69332911D1 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
ATE148918T1 (de) Für die co4-bindende domäne von hiv spezifische antikörper
GR1002294B (el) Συνδυασμενο εμβολιο για streptococcus ομαδας β.
ITVR940096A0 (it) Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
AU9179891A (en) Hiv reverse transcriptase vaccine
CA2156495A1 (en) Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
CA2160696A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0385909A3 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen
CA2160922A1 (en) Hiv immunogenic complexes
AU5695294A (en) Monoclonal antibodies against a carbohydrate-dependent epitope related to the V2 region of HIV-1 GP120

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0699077

Country of ref document: EP